Published

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Psychological medicine
Date: 2023-12-01
Source: PubMed
DOI: 10.1017/s0033291723001411
PubMed: 37264950

Authors

McCrone P Fisher H Knight C Harding R Schlag AK Nutt DJ Neill JC

Watch author

Derived topics and classifications

psilocybin Depression Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 7 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overview2026-07-13 Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation2026-06-03 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial2026-05-27 Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant Depression2026-03-01 Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications2026-03-01 Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model.2023-12-01

Related papers

Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant DepressionClinicalTrials.gov · 2026-07-30 Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)ClinicalTrials.gov · 2025-10-07 Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-makingInstituto Politécnico do Porto · 2026-02-27 Protecting patient autonomy in psychedelic-assisted psychotherapy: a nursing ethics perspectiveZenodo (CERN European Organization for Nuclear Research) · 2026-01-30 Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on AlcoholismClinicalTrials.gov · 2025-09-24